Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Phase II / III Follow-up Study to Assess Long-Term Efficacy and Safety of Three Different Dose Regimens of Oralgen Grass Pollen in Patients With Grass Pollen-Related Allergic Rhinoconjunctivitis (Follow-up Study to AB0602).
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Therapeutic Use
- 30 Jul 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record. (23 Sep 2008 )
- 30 Jul 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record. (23 Sep 2008 )
- 30 Jul 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record. (23 Sep 2008 )